Simvastatin vs Ezetimibe and Simvastatin — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

HMG-CoA Reductase Inhibitor

Simvastatin

Brand: ZOCOR

First FDA approval: 2006-12-20

HMG-CoA Reductase Inhibitor

Ezetimibe and Simvastatin

Brand: VYTORIN

First FDA approval: 2017-04-26

Lowest NADACAcquisition cost floor across all NDCs

$0.028Per unit

$0.318Per unit

Average NADACAcross all dosage forms and strengths

$0.395Up to $9.73

$1.79Up to $13.89

Generic manufacturersActive ANDA holders — FDA Orange Book

1154 total ANDAs filed

416 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$190.2MFull year

—Full year

Part D claims (CY24)Total fills, all strengths

22.1M6.9M beneficiaries

—— beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$9Per claim, all NDCs

—Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

5Minimal friction

3Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

3Limited friction

12Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes11 manufacturers

Yes4 manufacturers